Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
Acute Disease
Adolescent
Adult
Aged
Child
Chimerism
Female
Genetic Association Studies
Genetic Predisposition to Disease
Genotype
Graft vs Host Disease
/ genetics
HLA Antigens
/ metabolism
Hematopoietic Stem Cell Transplantation
Histocompatibility
Histocompatibility Antigens Class I
/ genetics
Histocompatibility Testing
Humans
Killer Cells, Natural
/ immunology
Leukemia
/ therapy
Male
Middle Aged
Polymorphism, Genetic
Receptors, KIR
/ genetics
Siblings
Young Adult
Acute leukemia
Chimerism
Graft versus host disease
Hematopoietic stem cell transplantation
Human leukocyte antigen
Killer immunoglobulin-like receptor
Journal
Human immunology
ISSN: 1879-1166
Titre abrégé: Hum Immunol
Pays: United States
ID NLM: 8010936
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
16
01
2020
revised:
06
03
2020
accepted:
14
03
2020
pubmed:
23
3
2020
medline:
20
2
2021
entrez:
23
3
2020
Statut:
ppublish
Résumé
In addition to T cells, NK cells can also participate in the outcome of hematopoietic stem cell transplantation (HSCT) mainly through the interaction between donor killer cell immunoglobulin-like receptors (KIRs) and recipient human leukocyte antigen (HLA) class I molecules. There is a risk of GVHD other than leukemia relapse after allogeneic HSCT that activation of donor NK cells in the absence of appropriate inhibitory ligands will be one of the reasons. To investigate the impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD and leukemia relapse in patients with acute leukemia after HSCT, 100 patients with acute leukemia who received HSCT from their HLA-matched siblings were included in this study. Genotypes of 16 KIR genes and two 2DS4 variants (full length and deleted alleles), along with HLA-A/B genotypes, were determined by PCR-SSP. HLA-C genotyping was done with the SSO-Luminex method. Chimerism analysis was done using 16 short tandem repeats (STRs) to detect early leukemia relapse. Acute (a)GVHD occurred in 38 patients, and 16 of them died during the study. None of the recipients showed any sign of leukemia relapse after HSCT. Full donor chimerism was observed in all tested patients during the first year after HSCT. Our results also indicated an increased risk of aGVHD in AA recipients with the C2/Cx, Bw4
Identifiants
pubmed: 32199702
pii: S0198-8859(20)30039-2
doi: 10.1016/j.humimm.2020.03.004
pii:
doi:
Substances chimiques
HLA Antigens
0
Histocompatibility Antigens Class I
0
Receptors, KIR
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-292Informations de copyright
Copyright © 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.